22
180
59
↑22
↓180
—59
Evidence suggests Iron maydecreaseAnemia.
217 studies (261 claims)
Moderate consensus
Typical effective dose 60 (25–110) mgacross 39 dosed studies
Study Claims
| Intervention | Direction | Endpoint | Type | Population | Dosage | Title |
|---|---|---|---|---|---|---|
| iron supplements (0, 1, or 2 mg · kg(-1) · day(-1)) | No effect - there were similar nonsignificant trends for | ID anemia | Human | marginally LBW infants (2000-2500 g) | 0, 1, or 2 mg/kg/day. | Iron supplementation until 6 months protects marginally low-birth-weight infants from iron deficiency during their first year of life.cited 24× |
| iron and folic acid | Decreases - reduces risk | anemia | Human | women and adolescents prior to pregnancy | Folic acid, iron, and vitamins A, B-complex, C, and E at approximately single recommended dietary allowance (RDA) doses, administered daily. | Multivitamin and iron supplementation to prevent periconceptional anemia in rural tanzanian women: a randomized, controlled trial.cited 20× |
| folic acid and iron | Decreases - significant reduction | risk of hypochromic microcytic anemia | Human | Non-pregnant women and adolescent girls aged 15-29 years | Folic acid, iron, and vitamins A, B-complex, C, and E at approximately single recommended dietary allowance (RDA) doses, administered daily. | Multivitamin and iron supplementation to prevent periconceptional anemia in rural tanzanian women: a randomized, controlled trial.cited 20× |
| EPO administered with the oral dose of iron | Increases - shows higher effectiveness | treatment of anemia caused by iron deficiency | Human | pregnant women with anemia caused by iron deficiency | Group II received 1000 IU EPO intravenously every three days with oral iron supplements; Group I received Ferrum Lek intramuscularly every two days. | Use of alternative methods in the treatment of anemia in pregnant women - prospective observational study.cited 2× |
| IV iron therapy | Decreases - Management of iron-deficiency anemia includes | iron-deficiency anemia | Human | surgical patients | Not specified | Preoperative anemia-screening clinics.cited 34× |
| iron supplementation | Decreases - Management of iron-deficiency anemia includes | iron-deficiency anemia | Human | surgical patients | Not specified | Preoperative anemia-screening clinics.cited 34× |
| Iron deficiency anemia (IDA) | No effect - is the most recognized type of | anemia | Human | patients with celiac disease (CD) | Not available | Iron Deficiency in Celiac Disease: Prevalence, Health Impact, and Clinical Management.cited 27× |
| iron-folic acid supplementation | Decreases - prevent | anemia | Human | — | Not specified | Adherence to iron-folic acid supplementation among pregnant women in Ethiopia: a systematic review and meta-analysis.cited 54× |
| iron-folic acid supplementation | Decreases - is the recommended strategy | iron deficiency anemia | Human | pregnant women | Not specified | Adherence to iron-folic acid supplementation among pregnant women in Ethiopia: a systematic review and meta-analysis.cited 54× |
| iron-folic acid supplementation | Decreases - is a central preventive measure for | maternal anemia | Human | maternal | Not specified | Effect of Maternal Education on Prenatal Adherence of Iron-folic Acid Supplementation in Ethiopia: A Systematic Review and Meta-analysis.cited 2× |
| iron-folic acid supplementation | Decreases - can be reduced | prevalence of maternal anemia | Human | — | Not specified | Maternal iron-folic acid supplementation programs: evidence of impact and implementation.cited 78× |
| iron supplementation in pregnancy | Decreases - has been advocated for decades as a means of controlling | anemia | Human | pregnancy women | Not specified | Iron interventions for women and children in low-income countries.cited 79× |
| 20 mg iron and 100 μg folic acid (IFA) supplementation for 100 days/year | No effect - anemia prevalence has remained high | anemia prevalence | Human | children <5 years of age in India | Daily (20 mg iron + 100 μg folic acid or 40 mg iron + 200 μg folic acid) and weekly (40 mg iron + 200 μg folic acid). | Relative efficacy of weekly and two differing doses of daily iron-folate supplementation in improving hemoglobin in mild and moderately anemic children between 3 and 5 years of age: a cluster randomized trial.cited 2× |
| twice weekly oral iron therapy | Decreases - resolved | anemia | Human | Jordanian children aged between 6 and 60 months with Hb estimate less than 11 gm/dl | Single weekly dose, two doses weekly, and daily dose (specific amounts not provided). | Comparison between once weekly, twice weekly, and daily oral iron therapy in Jordanian children suffering from iron deficiency anemia.cited 7× |
| twice weekly oral iron therapy | Decreases - recovery | anemia | Human | Jordanian children aged between 6 and 60 months with Hb estimate less than 11 gm/dl | Single weekly dose, two doses weekly, and daily dose (specific amounts not provided). | Comparison between once weekly, twice weekly, and daily oral iron therapy in Jordanian children suffering from iron deficiency anemia.cited 7× |
| once weekly oral iron therapy | Decreases - resolved | anemia | Human | Jordanian children aged between 6 and 60 months with Hb estimate less than 11 gm/dl | Single weekly dose, two doses weekly, and daily dose (specific amounts not provided). | Comparison between once weekly, twice weekly, and daily oral iron therapy in Jordanian children suffering from iron deficiency anemia.cited 7× |
| once weekly oral iron therapy | Decreases - recovery | anemia | Human | Jordanian children aged between 6 and 60 months with Hb estimate less than 11 gm/dl | Single weekly dose, two doses weekly, and daily dose (specific amounts not provided). | Comparison between once weekly, twice weekly, and daily oral iron therapy in Jordanian children suffering from iron deficiency anemia.cited 7× |
| daily oral iron therapy | Decreases - resolved | anemia | Human | Jordanian children aged between 6 and 60 months with Hb estimate less than 11 gm/dl | Single weekly dose, two doses weekly, and daily dose (specific amounts not provided). | Comparison between once weekly, twice weekly, and daily oral iron therapy in Jordanian children suffering from iron deficiency anemia.cited 7× |
| daily oral iron therapy | Decreases - recovery | anemia | Human | Jordanian children aged between 6 and 60 months with Hb estimate less than 11 gm/dl | Single weekly dose, two doses weekly, and daily dose (specific amounts not provided). | Comparison between once weekly, twice weekly, and daily oral iron therapy in Jordanian children suffering from iron deficiency anemia.cited 7× |
| directly observed iron-folic acid (IFA) supplementation | Decreases - reduction in anemia was 6% higher | prevalence of anemia | Human | pregnant women in a rural setting of north India | Not specified in the abstract. | Effect of directly observed oral iron supplementation during pregnancy on iron status in a rural population in Haryana: A randomized controlled trial.cited 13× |
| low iron level | Increases - is the most common cause of | anemia | Human | adolescent girls | Not specified | Gynecological care in young women: a high-risk period of life.cited 8× |
| nutrition and oral iron supplementation, particularly extended-release ferrous sulfate with mucoproteose | Decreases - minimizing the development and risks of | anemia | Human | this vulnerable population | Not specified | Gynecological care in young women: a high-risk period of life.cited 8× |
| erythropoiesis-stimulating agents (ESAs), together with iron supplementation | No effect - are the main tool for | anemia correction | Human | chronic kidney disease patients | Not specified | New erythropoiesis-stimulating agents and new iron formulations.cited 8× |
| daily supplementation of 60 mg elemental iron | Increases - is more efficacious than | prophylaxis of anemia | Human | pregnant women | 30 mg/day, 60 mg/day, and >60 mg/day of elemental iron | Efficacy of different doses of daily prophylactic iron supplementation in pregnant women: A systematic review and meta-analysis. |
| daily supplementation of ≤60 mg elemental iron | No effect - is equally efficacious compared to | prophylaxis of anemia | Human | pregnant women | 30 mg/day, 60 mg/day, and >60 mg/day of elemental iron | Efficacy of different doses of daily prophylactic iron supplementation in pregnant women: A systematic review and meta-analysis. |
| daily supplementation of 30 mg elemental iron | Decreases - is less efficacious than | prophylaxis of anemia | Human | pregnant women | 30 mg/day, 60 mg/day, and >60 mg/day of elemental iron | Efficacy of different doses of daily prophylactic iron supplementation in pregnant women: A systematic review and meta-analysis. |
| daily supplementation of >60 mg elemental iron | No effect - is equally efficacious compared to | prophylaxis of anemia | Human | pregnant women | 30 mg/day, 60 mg/day, and >60 mg/day of elemental iron | Efficacy of different doses of daily prophylactic iron supplementation in pregnant women: A systematic review and meta-analysis. |
| antenatal iron-folic acid use | Decreases - may reduce | anemia | Human | many countries | Biannual large-dose (exact amount not specified) | Nutrition and maternal, neonatal, and child health.cited 136× |
| administration of intravenous iron by intermittent administration (IA) | No effect - has the similar effects | iron supplement and anemia treatment | Human | maintenance hemodialysis (MHD) patients | 100 mg sucrose iron agents per session (continuous: every HD session; intermittent: once weekly), totaling 1000 mg. | Effect of frequency of intravenous iron administration on hemoglobin variability in maintenance hemodialysis patients.cited 5× |
| administration of intravenous iron by continuous administration (CA) | No effect - has the similar effects | iron supplement and anemia treatment | Human | maintenance hemodialysis (MHD) patients | 100 mg sucrose iron agents per session (continuous: every HD session; intermittent: once weekly), totaling 1000 mg. | Effect of frequency of intravenous iron administration on hemoglobin variability in maintenance hemodialysis patients.cited 5× |
| intraoperative and postoperative intravenous iron supplementation | Decreases - reduced rates of | postoperative anemia | Human | elective TJA patients | Not specified | Intraoperative and Postoperative Iron Supplementation in Elective Total Joint Arthroplasty: A Systematic Review.cited 2× |
| Iron supplementation | Decreases - reduced | anemia | Human | LMIC | Not specified | Nutritional Management of Low Birth Weight and Preterm Infants in Low- and Low Middle-Income Countries.cited 2× |
| iron supplementation | Decreases - can correct | anemia | Human | patients with cancer | Not Assessed | Cancer- and chemotherapy-induced anemia.cited 137× |
| iron supplementation | Decreases - correcting | anemia | Human | CKD patients | Not specified | New strategies for managing anemia of chronic kidney disease.cited 1× |
| iron (III)-carboxymaltose | Decreases - novel high dose iron formulations | anemia of CKD | Human | — | Not specified | New strategies for managing anemia of chronic kidney disease.cited 1× |
| iron supplementation | No effect - remain core components of anemia management | anemia | Human | children with chronic kidney disease (CKD) | Not specified | Anemia in chronic kidney disease.cited 62× |
| iron supplementation | No effect - a substantial number of children remain anemic despite these therapies | anemia | Human | children with chronic kidney disease (CKD) | Not specified | Anemia in chronic kidney disease.cited 62× |
| dialysate-delivered iron supplements | No effect - have been developed and may offer options for alternative anemia management | anemia management | Human | — | Not specified | Anemia in chronic kidney disease.cited 62× |
| iron supplementation | No effect - lack in effective | anemia | Human | pre-dialysis patients | Not specified | Iron deficiency across chronic kidney disease stages: Is there a reverse gender pattern?cited 9× |
| iron supplementation | Decreases - utility | anemia | Human | surgical patients | Not available | Perioperative Anemia: Prevention, Diagnosis, and Management Throughout the Spectrum of Perioperative Care.cited 78× |
| iron supplementation | Decreases - has traditionally included | anemia | Human | patients with chronic kidney disease (CKD) | Not Assessed | Current treatment practices for anemia in patients with chronic kidney disease and future opportunities with hypoxia-inducible factor prolyl hydroxylase inhibitors: a narrative review.cited 3× |
| iron supplementation | Decreases - was safe and effective in treating | anemia | Human | elderly patients undergoing hip or knee surgery | Not specified | Efficacy and safety of iron supplementation for the elderly patients undergoing hip or knee surgery: a meta-analysis of randomized controlled trials.cited 36× |
| iron supplementation | Increases - more frequently applied | anemia | Human | patients with anemia | Not specified | Effect of mycophenolate mofetil on hematological side effects incidence in renal transplant recipients.cited 15× |
| extensive iron supplementation | No effect - may be ineffective | anemia | Human | renal transplant recipients with deteriorated renal function | Not specified | Effect of mycophenolate mofetil on hematological side effects incidence in renal transplant recipients.cited 15× |
| iron supplementation | Decreases - benefits | anemia | Human | patients with heart failure | Not specified | Anemia, heart failure and evidence-based clinical management.cited 8× |
| Iron supplementation | Decreases - is one cornerstone of anemia management | anemia | Human | CKD patients | Not specified | The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients.cited 61× |
| iron supplementation | No effect - does not preempt anemia | anemia | Human | pregnancies | 20 mg/d, 40 mg/d, or 80 mg/d depending on hemoglobin levels. | Adapting iron dose supplementation in pregnancy for greater effectiveness on mother and child health: protocol of the ECLIPSES randomized clinical trial.cited 43× |
| iron supplementation | No effect - medical management option | anemia | Human | patients who refuse blood transfusion | Not specified | Management of the Jehovah's Witness in Obstetrics and Gynecology: A Comprehensive Medical, Ethical, and Legal Approach.cited 21× |
| iron supplementation | Decreases - is based on | anemia | Human | women with abnormal uterine bleeding | Not specified | Update on the management of abnormal uterine bleeding.cited 16× |
| iron supplementation | Decreases - was recommended | anemia | Human | patients with BRBNS and anemia | Not specified | Blue rubber bleb nevus syndrome: our experience and new endoscopic management.cited 15× |
| iron supplementation | Decreases - sufficient evidence to reduce | anemia | Human | — | Not specified | Nutrition for the Next Generation: Older Children and Adolescents.cited 48× |
| iron supplementation | No effect - unresponsive | anemia | Human | patients with hereditary spherocytosis | Not specified | Surgical management of hereditary spherocytosis Current strategies.cited 4× |
| iron supplementation | Decreases - is recommended | anemia | Human | all CKD patients with anemia | Not specified | Iron Deficiency Anemia in Chronic Kidney Disease.cited 137× |
| iron supplementation | Decreases - Prevention of iron shortage | anemia | Human | preterm infants | 2 mg/kg/day of oral elemental iron. | Iron Homeostasis Disruption and Oxidative Stress in Preterm Newborns.cited 32× |
| iron supplementation | No effect - frequently needed | anemia | Human | patients with active inflammatory bowel disease (IBD) | Not specified | Safety profile of intravenous iron in inflammatory bowel disease: an up-to-date overview. |
| intravenous iron supplementation | No effect - most effective therapy | IBD-associated iron deficiency anemia | Human | — | Not specified | Safety profile of intravenous iron in inflammatory bowel disease: an up-to-date overview. |
| iron supplementation | Decreases - should be implemented | anemia | Human | patients with IBD | Not specified | Iron Deficiency Anemia in Inflammatory Bowel Diseases-A Narrative Review.cited 42× |
| iron supplementation | Decreases - effective in ameliorating | anemia | Human | CRC surgery patients | Not specified | Iron Supplementation Effectively Ameliorates Anemia and Reduces the Need for Blood Transfusion in Patients Undergoing Colorectal Cancer Surgery: A Meta-Analysis.cited 3× |
| Iron supplementation | Decreases - recommended for | anemia | Human | adolescent females who have a menstrual cycle that lasts longer than 5 days | Not specified | Menstrual abnormality, maternal illiteracy, and household factors as main predictors of anemia among adolescent girls in Ethiopia: Systematic review and meta-analysis.cited 3× |
| iron supplementation | No effect - treatment of anemia | anemia | Human | neonatal population | Not available | Neonatal Anemia.cited 5× |
| Iron supplementation | Decreases - can also be used to treat | anemia | Human | patients in the postpartum period after severe PPH | Not specified | Patient Blood Management programs for post-partum hemorrhage.cited 3× |
| iron supplementation | Decreases - proposed to treat | anemia | Human | perioperative period | Not specified | Management of Preoperative Anemia.cited 3× |
| iron supplementation | Decreases - is the intervention of choice | anemia and other manifestations of iron deficiency | Human | target groups have already been identified as being iron-deficient | Not specified | Considerations for the safe and effective use of iron interventions in areas of malaria burden - executive summary.cited 23× |
| iron supplementation | Decreases - significantly decreased the risk of | anemia at delivery | Human | pregnant women in Dar es Salaam, Tanzania | 60 mg of iron, administered every 4 weeks. | Iron Supplementation in Iron-Replete and Nonanemic Pregnant Women in Tanzania: A Randomized Clinical Trial.cited 47× |
| iron supplementation | Decreases - significantly reduced the risk of | iron deficiency anemia | Human | pregnant women in Dar es Salaam, Tanzania | 60 mg of iron, administered every 4 weeks. | Iron Supplementation in Iron-Replete and Nonanemic Pregnant Women in Tanzania: A Randomized Clinical Trial.cited 47× |
| iron supplementation | No effect - did not significantly decrease the risk of | severe anemia | Human | pregnant women in Dar es Salaam, Tanzania | 60 mg of iron, administered every 4 weeks. | Iron Supplementation in Iron-Replete and Nonanemic Pregnant Women in Tanzania: A Randomized Clinical Trial.cited 47× |
| Iron supplementation | Decreases - could prevent | anemia cases | Human | children in Africa | Not specified | Childhood anemia and iron deficiency in sub-Saharan Africa - risk factors and prevention: A review.cited 33× |
| iron supplementation | No effect - recommended as | anemia control measures | Human | pregnant women | Not specified | Geophagy during pregnancy in Africa: a literature review.cited 61× |
| iron supplementation | Decreases - can treat | anemia of CKD | Human | children with chronic kidney disease (CKD) | Not specified | Anemia in children with chronic kidney disease.cited 45× |
| iron supplementation | No effect - was under-prescribed | anemia prevalence | Human | infants aged 6-12 months in Necochea | Not specified | Anemia and iron deficiency in infants aged 6-12 months in the city of Necochea: Prevalence and determinants. |
| adequate iron intake | No effect - was not a protective factor | development of anemia | Human | infants aged 6-12 months in Necochea | Not specified | Anemia and iron deficiency in infants aged 6-12 months in the city of Necochea: Prevalence and determinants. |
| iron supplementation | Decreases - reduced | anemia risk | Human | pregnant women | 300 mg ferrous sulfate + 0.40 mg folate daily. | Prenatal Iron Supplementation Reduces Maternal Anemia, Iron Deficiency, and Iron Deficiency Anemia in a Randomized Clinical Trial in Rural China, but Iron Deficiency Remains Widespread in Mothers and Neonates.cited 56× |
| Iron supplementation | Decreases - decrease | anemia symptoms | Human | — | Not specified | SAFETY AND EFFICACY OF INTRAVENOUS ADMINISTRATION OF IRON PREPARATIONS.cited 11× |
| Oral iron administration | No effect - is a treatment of choice | iron deficiency anemia | Human | — | Not specified | SAFETY AND EFFICACY OF INTRAVENOUS ADMINISTRATION OF IRON PREPARATIONS.cited 11× |
| iron supplementation | No effect - low adherence is a barrier | clinical management of iron deficiency anemia | Human | pediatric population | Not available | The perspective of primary health care pediatricians regarding childhood anemia and iron supplementation.cited 1× |
| iron supplementation | No effect - effect on | development of iron deficiency anemia | Human | 6-month-old infants who had been exclusively breastfed in the first 4 months of life | 1 mg/kg/day ferrous sulfate | Effect of iron supplementation on development of iron deficiency anemia in breastfed infants.cited 6× |
| iron supplementation | Decreases - could reduce the risk of | infant anemia | Human | infants during the first year of life | Not specified | The interplay between maternal-infant anemia and iron deficiency.cited 11× |
| iron supplementation | Decreases - benefits are well recognized | iron deficiency anemia | Human | anemic women | Not specified | Iron status of North American pregnant women: an update on longitudinal data and gaps in knowledge from the United States and Canada.cited 27× |
| universal iron supplementation | Decreases - recommended | adverse birth outcomes associated with maternal iron deficiency anemia | Human | pregnant women | Not specified | Iron status of North American pregnant women: an update on longitudinal data and gaps in knowledge from the United States and Canada.cited 27× |
| iron supplementation | Decreases - reduced the risk | iron deficiency anemia | Human | — | Not specified | Maternal and neonatal outcomes related to iron supplementation or iron status: a summary of meta-analyses.cited 39× |
| iron supplementation | Decreases - easily treated | iron deficiency anemia | Human | — | Not specified | Treating Preoperative Anemia to Improve Patient Outcomes After Orthopaedic Surgery.cited 9× |
| intravenous iron supplementation | No effect - has not been clearly shown | anemia related to acute blood loss and underlying conditions in trauma | Human | cases of trauma | Not specified | Treating Preoperative Anemia to Improve Patient Outcomes After Orthopaedic Surgery.cited 9× |
| iron supplementation | Decreases - can reduce | iron deficiency anemia | Human | the general population | Not Assessed | Anemia, Iron Status, and HIV: A Systematic Review of the Evidence.cited 44× |
| Iron supplementation | Decreases - standard intervention for the prevention and treatment | iron deficiency anemia (IDA) | Human | developed and developing countries | Not specified | Effects of probiotics on immunity and iron homeostasis: A mini-review.cited 6× |
| Iron supplementation | Decreases - reduced | iron-deficiency anemia | Human | — | Not specified | Effective nonvaccine interventions to be considered alongside human papilloma virus vaccine delivery.cited 11× |
| Iron supplementation | Affects - prescribed | iron-deficiency anemia | Human | the patient | Not specified | A 10-year delayed diagnosis of blue rubber bleb nevus syndrome characterized by refractory iron-deficiency anemia: A case report and literature review.cited 11× |
| Laparotomy with resection of the small bowel lesions and iron supplementation | Decreases - cured | iron-deficiency anemia | Human | this patient | Not specified | A 10-year delayed diagnosis of blue rubber bleb nevus syndrome characterized by refractory iron-deficiency anemia: A case report and literature review.cited 11× |
| iron supplementation | No effect - not responsive | long-term iron deficiency anemia | Human | IBD patients | Not Assessed | Celiac disease, non-celiac gluten sensitivity and inflammatory bowel disease.cited 11× |
| iron supplementation | Decreases - improvements were noted | maternal anemia | Human | women | Not specified | Vitamin and Mineral Supplementation During Pregnancy on Maternal, Birth, Child Health and Development Outcomes in Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis.cited 122× |
| iron-folic (IFA) supplementation | Decreases - showed notable improvement | maternal anemia | Human | women | Not specified | Vitamin and Mineral Supplementation During Pregnancy on Maternal, Birth, Child Health and Development Outcomes in Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis.cited 122× |
| iron supplementation | Decreases - was associated with decreased risk of | maternal iron deficiency anemia at term | Human | pregnant women | Not specified | Screening and Supplementation for Iron Deficiency and Iron Deficiency Anemia During Pregnancy: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.cited 11× |
| routine prenatal iron supplementation | Decreases - reduces the incidence of | iron deficiency anemia | Human | pregnant women | Not specified | Screening and Supplementation for Iron Deficiency and Iron Deficiency Anemia During Pregnancy: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.cited 11× |
| Iron supplementation | No effect - commonly recommended for the prevention and treatment | maternal iron deficiency (ID) or iron deficiency anemia (IDA) | Human | — | Not specified | The Effects of Prenatal Iron Supplementation on Offspring Neurodevelopment in Upper Middle- or High-Income Countries: A Systematic Review.cited 2× |
| iron supplementation | Decreases - remains an option | mild anemia | Human | patients with mild anemia from small bowel vascular lesions | Not specified | Diagnosis and therapeutic strategies for small bowel vascular lesions.cited 50× |
| iron supplementation | Decreases - has proven to be highly effective | postpartum anemia | Human | women with iron deficiency and iron deficiency anemia | Not specified | Current concepts in postpartum anemia management.cited 6× |
| iron supplementation | No effect - hallmark therapy | preoperative anemia treatment | Human | patients with preoperative anemia | Not specified | Adverse events of iron and/or erythropoiesis-stimulating agent therapy in preoperatively anemic elective surgery patients: a systematic review.cited 4× |
| iron supplementation | No effect - treating | renal anemia | Human | patients | Not specified | Renal anemia: current treatments and emerging molecules.cited 5× |
| iron supplementation | Increases - incomplete adherence | risk factor for iron deficiency/iron deficiency anemia | Human | populations with a high prevalence of iron deficiency | Not specified | Adherence to iron supplementation during the first year of life infants in Izmir, Turkey. |
| iron supplementation | Decreases - reduced | risk of anemia | Human | primary-school-aged children | Not specified in the abstract. | Effects of daily iron supplementation in primary-school-aged children: systematic review and meta-analysis of randomized controlled trials.cited 86× |
| iron supplementation | Decreases - can reduce | the severity of anemia | Human | patients with CKD | Ferumoxytol (1.02 g over 2 doses) or iron sucrose (1.0 g over 10 doses) during a 5-week treatment period. | The Ferumoxytol for Anemia of CKD Trial (FACT)-a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale.cited 7× |
| iron supplementation | Decreases - underutilized | treatment of anemia in elderly | Human | elderly | Not specified | Treatment options for anemia in the elderly.cited 9× |
| supplementation with hematinics, including group B vitamins and iron | No effect - limited | therapeutic approaches to anemia in elderly | Human | elderly | Not specified | Treatment options for anemia in the elderly.cited 9× |
| new oral and intravenous iron preparations | Increases - look promising | treatment of anemia | Human | elderly | Not specified | Treatment options for anemia in the elderly.cited 9× |
| Iron chelation therapy with deferasirox | Decreases - improved | anemia | Human | 64-year-old man with aceruloplasminemia | Not specified | Deferasirox Might Be Effective for Microcytic Anemia and Neurological Symptoms Associated with Aceruloplasminemia: A Case Report and Review of the Literature.cited 8× |
| extruded rice grains fortified with multiple micronutrients with low-iron (6.25 mg) concentration | Decreases - paired analyses revealed a small reduction | anemia prevalence | Human | 6- to 12-y-old, low-income school children in Bangalore, India | Not specified for Vitamin A (only iron concentrations: 6.25 mg or 12.5 mg). | Multiple micronutrient-fortified rice affects physical performance and plasma vitamin B-12 and homocysteine concentrations of Indian school children.cited 30× |
| extruded rice grains fortified with multiple micronutrients with high-iron (12.5 mg) concentration | Decreases - paired analyses revealed a small reduction | anemia prevalence | Human | 6- to 12-y-old, low-income school children in Bangalore, India | Not specified for Vitamin A (only iron concentrations: 6.25 mg or 12.5 mg). | Multiple micronutrient-fortified rice affects physical performance and plasma vitamin B-12 and homocysteine concentrations of Indian school children.cited 30× |
| iron syrup | Decreases - remained lower | prevalences of anemia, iron deficiency, and iron deficiency anemia | Human | children who received iron syrup | Daily supplementation (exact dosage not specified in the abstract). | Benefits and Risks of Iron Interventions in Infants in Rural Bangladesh.cited 36× |
| iron supplementation during pregnancy | Decreases - may have benefits beyond the prevention | iron-deficiency anemia | Human | nonanemic women with low serum ferritin | 60 mg elemental iron (as ferrous sulfate) daily until delivery. | Impact of prophylactic iron supplementation in healthy pregnant women on maternal iron status and birth outcome.cited 26× |
| therapeutic iron | Decreases - is associated with beneficial effects | anemia | Human | children living with HIV in India | Not specified | Anemia, diet and therapeutic iron among children living with HIV: a prospective cohort study.cited 23× |
| Universal prenatal daily iron-folic acid (IFA) supplements | Decreases - are recommended to reduce the risk of | maternal anemia | Human | pregnant women | Daily 400 μg folic acid (control), FA plus 30 mg iron, or FA, iron, plus 13 additional micronutrients. | Iron-containing micronutrient supplementation of Chinese women with no or mild anemia during pregnancy improved iron status but did not affect perinatal anemia.cited 18× |
| preoperative intravenous infusion of iron | Decreases - was associated with lower incidence | anemia | Human | patients undergoing coronary artery bypass grafting | Single intravenous dose of ferric carboxymaltose (1000 mg in 100 mL saline). | Intravenous iron supplementation treats anemia and reduces blood transfusion requirements in patients undergoing coronary artery bypass grafting-A prospective randomized trial.cited 15× |
| strategies to reduce iron deficiency anemia | Decreases - reduced | iron deficiency anemia | Human | infancy | Not specified | Promoting Early Child Development With Interventions in Health and Nutrition: A Systematic Review.cited 60× |
| iron supplementation alone | No effect - benefits and harms | chemotherapy-induced anemia | Human | — | Not specified | Iron Supplementation for Chemotherapy-Induced Anemia in Patients Receiving Erythropoiesis-Stimulating Agents.cited 4× |
| oral iron supplementation | Increases - superiority | treatment of chemotherapy-induced anemia | Human | — | Not specified | Iron Supplementation for Chemotherapy-Induced Anemia in Patients Receiving Erythropoiesis-Stimulating Agents.cited 4× |
| parenteral iron | Increases - superiority | treatment of chemotherapy-induced anemia | Human | — | Not specified | Iron Supplementation for Chemotherapy-Induced Anemia in Patients Receiving Erythropoiesis-Stimulating Agents.cited 4× |
| iron as an adjunct to erythropoiesis-stimulating agents (ESAs) | No effect - benefits and harms | chemotherapy-induced anemia | Human | — | Not specified | Iron Supplementation for Chemotherapy-Induced Anemia in Patients Receiving Erythropoiesis-Stimulating Agents.cited 4× |
| weekly iron-folic acid (IFA) supplements | No effect - did not reduce | anemia | Human | nonpregnant Malaysian women | 60 mg Fe with 0, 0.4, or 2.8 mg folic acid once weekly. | The Inclusion of Folic Acid in Weekly Iron-Folic Acid Supplements Confers no Additional Benefit on Anemia Reduction in Nonpregnant Women: A Randomized Controlled Trial in Malaysia. |
| iron replacement therapy | Decreases - treated | iron-deficiency anemia | Human | patients with diabetes mellitus and Hashimoto's thyroiditis | Not specified | Autoimmune Gastritis in Pediatrics: A Review of 3 Cases.cited 5× |
| iron replacement therapy | Decreases - treated | iron-deficiency anemia | Human | patients with diabetes mellitus and Addison's disease; and diabetes mellitus and Hashimoto's thyroiditis | Not specified | Autoimmune Gastritis in Pediatrics: A Review of 3 Cases.cited 5× |
| erythropoiesis-stimulating agents and iron supplementation | No effect - Current management of anemia | anemia | Human | patients with advanced CKD | Not specified | Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients.cited 108× |
| intravenous iron therapy | No effect - is reserved for | iron deficiency anemia | Human | patients with intolerance or unresponsiveness of oral iron | Varies by formulation (iron dextran, iron derisomaltose, ferric carboxymaltose, ferrumoxytol, iron sucrose, sodium ferric gluconate); specific doses not detailed. | Intravenous iron supplementation therapy.cited 45× |
| iron supplementation with or without folic acid | No effect - uncertain of the effect | anemia | Human | adolescents aged 10-19 years in low- and middle-income countries (LMICs) | Not specified | Effects of Preventive Nutrition Interventions among Adolescents on Health and Nutritional Status in Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis.cited 23× |
| iron supplementation with or without folic acid | No effect - uncertain of the effect | anemia | Human | adolescents aged 10-19 years in low- and middle-income countries (LMICs) | Not specified | Effects of Preventive Nutrition Interventions among Adolescents on Health and Nutritional Status in Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis.cited 23× |
| iron supplementation, 66 mg elemental iron daily as ferrous fumarate | Decreases - had a low frequency of | iron deficiency anemia (IDA) | Human | the iron group | 66 mg elemental iron daily as ferrous fumarate. | Iron supplementation in pregnant Danish women revisited: Effects on prepartum and postpartum iron deficiency, anemia, serum erythropoietin; including iron status, erythropoietin and anthropometrics in newborns. A randomized, placebo-controlled study.cited 4× |
| iron supplementation, 66 mg elemental iron daily as ferrous fumarate | Decreases - had a low frequency of | iron deficiency anemia (IDA) | Human | the iron group | 66 mg elemental iron daily as ferrous fumarate. | Iron supplementation in pregnant Danish women revisited: Effects on prepartum and postpartum iron deficiency, anemia, serum erythropoietin; including iron status, erythropoietin and anthropometrics in newborns. A randomized, placebo-controlled study.cited 4× |
| iron supplementation therapy | No effect - may be considered | anemia of inflammation | Human | patients where underlying disease and/or anemia are not resolved | Not specified | Physiology and Inflammation Driven Pathophysiology of Iron Homeostasis-Mechanistic Insights into Anemia of Inflammation and Its Treatment.cited 66× |
| untargeted iron supplementation | Decreases - recommends | anemia | Human | women of reproductive age (WRA) in countries where anemia prevalence is greater than 40% | Not specified in the abstract. | The Effect of Oral Iron Supplementation on Gut Microbial Composition: a Secondary Analysis of a Double-Blind, Randomized Controlled Trial among Cambodian Women of Reproductive Age.cited 6× |
| Weekly iron and folic acid supplementation (WIFAS) | Decreases - reduces | anemia | Human | — | 60 mg Fe as ferrous fumarate with 0 mg, 0.4 mg, or 2.8 mg folic acid, consumed once weekly. | Perspective: Weekly Iron and Folic Acid Supplementation (WIFAS): A Critical Review and Rationale for Inclusion in the Essential Medicines List to Accelerate Anemia and Neural Tube Defects Reduction.cited 17× |
| Postoperative oral iron | No effect - is of little value | postoperative anemia | Human | patients undergoing major surgery | Not specified | Management of Perioperative Iron Deficiency Anemia.cited 61× |
| Intravenous iron | No effect - should preferentially be used | moderate-to-severe iron deficiency anemia | Human | patients undergoing major surgery | Not specified | Management of Perioperative Iron Deficiency Anemia.cited 61× |
| Intravenous iron | No effect - should preferentially be used | postoperative anemia management | Human | patients undergoing major surgery | Not specified | Management of Perioperative Iron Deficiency Anemia.cited 61× |
| Preoperative oral iron | No effect - may have a role | mild-to-moderate anemia | Human | patients undergoing major surgery | Not specified | Management of Perioperative Iron Deficiency Anemia.cited 61× |
| once weekly iron supplementation (IS) | No effect - no significant change | anemia prevalence | Human | infants aged 6-18 months | 25 mg elemental iron once weekly (Group-A) or twice weekly (Group-B). | Prevention and Treatment of Anemia in Infants through Supplementation, Assessing the Effectiveness of Using Iron Once or Twice Weekly.cited 4× |
| twice weekly iron supplementation (IS) | Decreases - reduced | anemia prevalence | Human | infants aged 6-18 months | 25 mg elemental iron once weekly (Group-A) or twice weekly (Group-B). | Prevention and Treatment of Anemia in Infants through Supplementation, Assessing the Effectiveness of Using Iron Once or Twice Weekly.cited 4× |
| erythropoietin or iron supplementation | No effect - evaluated the efficacy | treating anemia | Human | patients with CHF | Not specified | Anemia in heart failure: should we supplement iron in patients with chronic heart failure?cited 12× |
| oral iron supplementation | No effect - poor response | intractable anemia | Human | An 11-year-old boy with a 6-year history of intractable anemia | Not specified | Hirschsprung's disease presenting as intractable anemia: a report of two cases and review of the literature.cited 2× |
| oral iron supplementation | No effect - poor response | intractable anemia | Human | A 19-month-old boy with a 3-month history of intractable anemia | Not specified | Hirschsprung's disease presenting as intractable anemia: a report of two cases and review of the literature.cited 2× |
| oral iron supplementation | Decreases - can be treated effectively | iron deficiency and iron-deficiency anemia | Human | many patient populations | Not specified | Iron Sucrose: A Wealth of Experience in Treating Iron Deficiency.cited 15× |
| intravenous iron administration | Decreases - is recommended | iron deficiency and iron-deficiency anemia | Human | patients who are unable to take or who do not respond to oral iron therapy | Not specified | Iron Sucrose: A Wealth of Experience in Treating Iron Deficiency.cited 15× |
| intravenous iron administration | Decreases - has become first-line treatment | iron deficiency and iron-deficiency anemia | Human | patients with end-stage kidney disease, chronic heart failure, and inflammatory bowel disease | Not specified | Iron Sucrose: A Wealth of Experience in Treating Iron Deficiency.cited 15× |
| oral iron supplementation | Decreases - resolved | iron deficiency anemia | Human | patients with collagenous gastritis | Not specified | Pediatric Collagenous Gastritis and Colitis: A Case Series and Review of the Literature.cited 26× |
| oral iron supplementation | No effect - refractory to | iron deficiency anemia (IDA) | Human | some celiac patients | Not specified | Persistent Iron Deficiency Anemia in Patients with Celiac Disease Despite a Gluten-Free Diet.cited 35× |
| Oral iron supplementation | Decreases - is the recommended treatment | iron deficiency anemia | Human | in pregnancy | Not specified | Anemia in pregnancy.cited 48× |
| Parenteral iron | Decreases - can also be used | iron deficiency anemia | Human | in severe or refractory cases in pregnancy | Not specified | Anemia in pregnancy.cited 48× |
| oral iron supplementation | No effect - unresponsive | iron deficiency anemia | Human | multiple family members in several kindreds | Not specified | Iron-refractory iron deficiency anemia (IRIDA).cited 57× |
| parenteral iron therapy | No effect - only partially responsive | iron deficiency anemia | Human | multiple family members in several kindreds | Not specified | Iron-refractory iron deficiency anemia (IRIDA).cited 57× |
| Oral iron supplementation | Decreases - can be an effective strategy to treat and prevent | iron deficiency anemia (IDA) | Human | young women | 60-120 mg elemental iron as a ferrous salt, given with ascorbic acid on alternate mornings. | Oral iron supplementation in iron-deficient women: How much and how often?cited 76× |
| oral iron supplementation | Decreases - Management of iron deficiency anemia is done classically via | iron deficiency anemia | Human | pregnant women | Not specified | Recognizing who is at risk for postpartum hemorrhage: targeting anemic women and scoring systems for clinical use.cited 10× |
| intravenous iron | Decreases - is a good alternative to oral iron | iron deficiency anemia | Human | patients unable to tolerate oral iron, not responding, or presenting with a new diagnosis very late in pregnancy | Not specified | Recognizing who is at risk for postpartum hemorrhage: targeting anemic women and scoring systems for clinical use.cited 10× |
| oral iron supplementation | No effect - evaluate the impact | iron deficiency anemia | Human | patients with rectal cancer receiving preoperative chemoradiotherapy | Not specified | Intravenous versus oral iron supplementation for iron deficiency anemia in patients with rectal cancer undergoing neoadjuvant chemoradiotherapy: a study protocol for a randomized controlled trial. |
| intravenous iron supplementation | No effect - evaluate the impact | iron deficiency anemia | Human | patients with rectal cancer receiving preoperative chemoradiotherapy | Not specified | Intravenous versus oral iron supplementation for iron deficiency anemia in patients with rectal cancer undergoing neoadjuvant chemoradiotherapy: a study protocol for a randomized controlled trial. |
| oral iron supplementation | Decreases - are both effective strategies to reduce | iron-deficiency anemia (IDA) | Human | infants and young children in Sub-Saharan Africa | ≥12.5 mg iron dose (absorption typically <20%). | The effects of iron fortification and supplementation on the gut microbiome and diarrhea in infants and children: a review.cited 163× |
| iron-containing micronutrient powders (MNPs) | Decreases - are both effective strategies to reduce | iron-deficiency anemia (IDA) | Human | infants and young children in Sub-Saharan Africa | ≥12.5 mg iron dose (absorption typically <20%). | The effects of iron fortification and supplementation on the gut microbiome and diarrhea in infants and children: a review.cited 163× |
| oral iron supplementation | Decreases - is usually efficacious in correcting | iron-deficiency anemia | Human | — | Not specified | Oral iron supplementation: new formulations, old questions.cited 10× |
| Oral iron supplementation | No effect - is the cornerstone for the management | iron-deficiency anemia | Human | — | Twice daily (specific amount not provided). | An active new formulation of iron carried by aspartyl casein for iron-deficiency anemia: results of the ACCESS trial. |
| Oral iron supplementation | No effect - may not be effective | iron deficiency/iron deficiency anemia | Human | many of these patients | Not specified | Iron Deficiency Related to Obesity. |
| oral iron supplementation | Decreases - should be used | mild anemia | Human | EB patients | Not specified (oral iron for mild anemia; iron infusion for moderate to severe anemia). | Consensus guidelines for diagnosis and management of anemia in epidermolysis bullosa.cited 7× |
| iron infusion | Decreases - is reserved for | moderate to severe anemia | Human | EB patients | Not specified (oral iron for mild anemia; iron infusion for moderate to severe anemia). | Consensus guidelines for diagnosis and management of anemia in epidermolysis bullosa.cited 7× |
| erythropoiesis-stimulating agents (ESA) in conjunction with iron supplementation | No effect - has been the mainstay of treatment | anemia | Human | chronic kidney disease (CKD) | Not specified | Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors.cited 30× |
| daily liquid iron prophylaxis for 100 days in a year | Decreases - significant reduction in the prevalence of | nutritional anemia | Human | children 6 to 35 months of age | Weekly iron-folic acid tablets for adolescent girls; daily liquid iron prophylaxis for children for 100 days/year. | Community-led initiative for control of anemia among children 6 to 35 months of age and unmarried adolescent girls in rural Wardha, India.cited 27× |
| weekly iron-folic acid tablets | Decreases - significant reduction in the prevalence of | nutritional anemia | Human | adolescent girls | Weekly iron-folic acid tablets for adolescent girls; daily liquid iron prophylaxis for children for 100 days/year. | Community-led initiative for control of anemia among children 6 to 35 months of age and unmarried adolescent girls in rural Wardha, India.cited 27× |
| prophylactic iron supplementation with ferrous sulfate | Decreases - recommended to prevent | iron deficiency anemia | Human | post-RYGB patients | Not specified | Malabsorption anemia and iron supplement induced constipation in post-Roux-en-Y gastric bypass (RYGB) patients.cited 11× |
| therapeutic iron supplementation | Decreases - requires lifelong behavioral change to ensure | iron deficiency anemia | Human | post-RYGB patients | Not specified | Malabsorption anemia and iron supplement induced constipation in post-Roux-en-Y gastric bypass (RYGB) patients.cited 11× |
| iron-folic acid (IFA) | No effect - did not affect | anemia prevalence | Human | infants | FA (400 μg daily), IFA (FA + 30 mg Fe daily), MMN (FA + Fe + 13 micronutrients daily). | Prenatal iron containing supplements provided to Chinese women with no or mild anemia had no effect on hemoglobin concentration in post-partum women or their infants at 6 and 12 months of age.cited 6× |
| iron-folic acid (IFA) | No effect - did not affect | prevalence of anemia | Human | post-partum women | FA (400 μg daily), IFA (FA + 30 mg Fe daily), MMN (FA + Fe + 13 micronutrients daily). | Prenatal iron containing supplements provided to Chinese women with no or mild anemia had no effect on hemoglobin concentration in post-partum women or their infants at 6 and 12 months of age.cited 6× |
| iron-folic acid | No effect - is still prevalent | iron deficiency anemia (IDA) | Human | India | Not specified | Sugarcane Molasses - A Potential Dietary Supplement in the Management of Iron Deficiency Anemia.cited 12× |
| iron-folic acid | Decreases - reduced | risk of anemia | Human | children under-five in LMICs | Not specified | Micronutrient Supplementation and Fortification Interventions on Health and Development Outcomes among Children Under-Five in Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis.cited 128× |
| iron alone | Decreases - reduced | risk of anemia | Human | children under-five in LMICs | Not specified | Micronutrient Supplementation and Fortification Interventions on Health and Development Outcomes among Children Under-Five in Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis.cited 128× |
| iron-folic acid | Decreases - reduced | third-trimester maternal anemia | Human | nulliparous pregnant women with mild or no anemia | 30 mg iron plus 400 μg folic acid daily, with or without 13 additional vitamins and minerals. | Micronutrient supplementation and pregnancy outcomes: double-blind randomized controlled trial in China.cited 61× |
| iron-folic acid and other micronutrients | Decreases - reduced | third-trimester maternal anemia | Human | nulliparous pregnant women with mild or no anemia | 30 mg iron plus 400 μg folic acid daily, with or without 13 additional vitamins and minerals. | Micronutrient supplementation and pregnancy outcomes: double-blind randomized controlled trial in China.cited 61× |
| iron-folic acid and other micronutrient supplements | Decreases - prevented | later pregnancy anemia | Human | Chinese women with no or mild anemia | 30 mg iron plus 400 μg folic acid daily, with or without 13 additional vitamins and minerals. | Micronutrient supplementation and pregnancy outcomes: double-blind randomized controlled trial in China.cited 61× |
| erythropoietin therapy and iron supplementation | Decreases - has traditionally been treated with, with great success | anemia in chronic kidney disease | Human | adult and pediatric patients with chronic kidney disease | Not specified | HIF stabilizers in the management of renal anemia: from bench to bedside to pediatrics.cited 25× |
| novel phosphate binders containing iron | Decreases - may reduce the need for | erythropoiesis-stimulating agents and intravenous (IV) iron for anemia management | Human | patients on maintenance hemodialysis (MHD) | Not specified | Novel iron-containing phosphate binders and anemia treatment in CKD: oral iron intake revisited.cited 18× |
| novel iron-containing phosphate binders, such as ferric citrate | Increases - unexpected efficacy in repleting insufficient iron stores and improving | anemia of CKD | Human | patients with chronic kidney disease (CKD) | Not specified | Novel iron-containing phosphate binders and anemia treatment in CKD: oral iron intake revisited.cited 18× |
| Intermittent iron supplementation | Decreases - associated with reduced risk | anemia | Human | children aged <5 y | Not specified (daily and intermittent iron supplementation mentioned without dosage details). | The Impact of Nutrition-Specific and Nutrition-Sensitive Interventions on Hemoglobin Concentrations and Anemia: A Meta-review of Systematic Reviews.cited 14× |
| Intermittent iron supplementation | Decreases - associated with reduced risk | anemia | Human | children older than 5 y | Not specified (daily and intermittent iron supplementation mentioned without dosage details). | The Impact of Nutrition-Specific and Nutrition-Sensitive Interventions on Hemoglobin Concentrations and Anemia: A Meta-review of Systematic Reviews.cited 14× |
| Daily iron supplementation | Decreases - associated with reduced risk | anemia | Human | children aged <5 y | Not specified (daily and intermittent iron supplementation mentioned without dosage details). | The Impact of Nutrition-Specific and Nutrition-Sensitive Interventions on Hemoglobin Concentrations and Anemia: A Meta-review of Systematic Reviews.cited 14× |
| Daily iron supplementation | Decreases - associated with reduced risk | anemia | Human | children older than 5 y | Not specified (daily and intermittent iron supplementation mentioned without dosage details). | The Impact of Nutrition-Specific and Nutrition-Sensitive Interventions on Hemoglobin Concentrations and Anemia: A Meta-review of Systematic Reviews.cited 14× |
| Daily iron-folic acid supplementation | Decreases - associated with reduced risk | anemia | Human | pregnant women | Not specified (daily and intermittent iron supplementation mentioned without dosage details). | The Impact of Nutrition-Specific and Nutrition-Sensitive Interventions on Hemoglobin Concentrations and Anemia: A Meta-review of Systematic Reviews.cited 14× |
| Intermittent iron supplementation | Decreases - reduces | anemia risk | Human | menstruating girls and women | Not specified | Review of intervention products for use in the prevention and control of anemia.cited 6× |
| Daily iron supplementation | Decreases - reduces the risk | anemia | Human | infants, children, and pregnant women | Not specified | Review of intervention products for use in the prevention and control of anemia.cited 6× |
| Fortifying wheat flour with iron | Decreases - reduces the risk | anemia | Human | the overall population | Not specified | Review of intervention products for use in the prevention and control of anemia.cited 6× |
| Fortification of salt with iodine and iron | Decreases - promising interventions to prevent | anemia | Human | — | Not specified | Review of intervention products for use in the prevention and control of anemia.cited 6× |
| Intermittent iron supplementation | Decreases - reduces | risk of anemia | Human | children | Not specified | Interventions to address maternal and childhood undernutrition: current evidence.cited 12× |
| daily iron supplementation | Decreases - results in a reduction | incidence of anemia | Human | women | Not specified | Interventions to address maternal and childhood undernutrition: current evidence.cited 12× |
| intravenous (IV) iron | No effect - has been managed primarily through | anemia | Human | end-stage renal disease patients maintained by hemodialysis | Not mentioned | Safety of intravenous iron in hemodialysis patients.cited 17× |
| intravenous (IV) iron | Decreases - reduces rates | anemia at the time of admission for delivery | Human | pregnant women with IDA | Single 1,000-mg dose of IV low-molecular weight iron dextran over one hour vs. oral iron (specific dosage not detailed). | Intravenous versus Oral Iron for Iron-Deficiency Anemia in Pregnancy (IVIDA): A Randomized Controlled Trial.cited 9× |
| intravenous (IV) iron | Decreases - significantly reduced | maternal anemia at delivery (hgb < 11 g/dL) | Human | pregnant women with IDA | Single 1,000-mg dose of IV low-molecular weight iron dextran over one hour vs. oral iron (specific dosage not detailed). | Intravenous versus Oral Iron for Iron-Deficiency Anemia in Pregnancy (IVIDA): A Randomized Controlled Trial.cited 9× |
| IV iron | Decreases - decreases rates | anemia on admission for delivery | Human | pregnant women with IDA | Single 1,000-mg dose of IV low-molecular weight iron dextran over one hour vs. oral iron (specific dosage not detailed). | Intravenous versus Oral Iron for Iron-Deficiency Anemia in Pregnancy (IVIDA): A Randomized Controlled Trial.cited 9× |
| Intravenous iron | Decreases - to correct | both pregnancy-related and hemorrhage-related iron deficiency anemia | Human | patients with pregnancy-related and hemorrhage-related iron deficiency anemia | Not specified | Strategies to reduce blood product utilization in obstetric practice.cited 9× |
| intravenous (i.v.) iron | No effect - efficacy and tolerability has been clinically evaluated and reviewed | cancer-related anemia and iron deficiency | Human | — | Not specified | Epidemiological and nonclinical studies investigating effects of iron in carcinogenesis--a critical review.cited 53× |
| intravenous iron | Increases - to expedite | treatment of iron deficiency anemia | Human | — | Not specified | Screening, Treatment, and Monitoring of Iron Deficiency Anemia in Pregnancy and Postpartum.cited 6× |
| intravenous iron supplementation | No effect - may be of advantage | aggravated anemia or flares of IBD | Human | patients with aggravated anemia or flares of IBD | Not specified | Management of Iron-Deficiency Anemia in Inflammatory Bowel Disease: A Systematic Review.cited 57× |
| intravenous iron supplementation | No effect - is the therapy of choice | iron-deficiency anemia | Human | patients with IBD flares and inadequate responses to or side effects with oral preparations | Not specified | Management of Iron-Deficiency Anemia in Inflammatory Bowel Disease: A Systematic Review.cited 57× |
| oral iron therapy | No effect - should be preferred | iron deficiency anemia | Human | patients with quiescent disease stages and trivial iron deficiency anemia | Not specified | Management of Iron-Deficiency Anemia in Inflammatory Bowel Disease: A Systematic Review.cited 57× |
| Intravenous iron supplementation | Decreases - is increasingly used to safely and effectively correct | iron deficiency anemia | Human | — | Not specified | No longer to be ignored: Hypophosphatemia following intravenous iron administration.cited 1× |
| intravenous iron supplementation | Increases - benefit of | iron deficiency with or without anemia | Human | HF patients | Not specified | Non-cardiac comorbidities in heart failure: an update on diagnostic and management strategies.cited 2× |
| inadequate iron supplementation | No effect - not apparently associated with | maternal anemia | Human | pregnant women in Indonesia | Not specified | Nutritional contributors to maternal anemia in Indonesia: Chronic energy deficiency and micronutrients.cited 6× |
| Weekly iron supplementation | No effect - did not reduce | anemia | Human | young, mostly adolescent menstruating women | 60 mg iron and 2.8 mg folic acid weekly. | Effects of Weekly Iron and Folic Acid Supplements on Malaria Risk in Nulliparous Women in Burkina Faso: A Periconceptional, Double-Blind, Randomized Controlled Noninferiority Trial.cited 21× |
| Weekly iron supplementation | No effect - did not reduce | anemia | Human | women in early pregnancy | 60 mg iron and 2.8 mg folic acid weekly. | Effects of Weekly Iron and Folic Acid Supplements on Malaria Risk in Nulliparous Women in Burkina Faso: A Periconceptional, Double-Blind, Randomized Controlled Noninferiority Trial.cited 21× |
| weekly iron supplementation (4 mg/kg/week) | Decreases - had a higher prevalence of | iron deficiency anemia (IDA) | Human | infants | Daily (1 mg/kg/day) or weekly (4 mg/kg/week) iron supplementation. | Effectiveness of weekly and daily iron administration for the prevention of iron deficiency anemia in infants.cited 2× |
| weekly iron supplementation (4 mg/kg/week) | No effect - no significant differences in effectiveness were observed between | iron deficiency anemia (IDA) | Human | infants | Daily (1 mg/kg/day) or weekly (4 mg/kg/week) iron supplementation. | Effectiveness of weekly and daily iron administration for the prevention of iron deficiency anemia in infants.cited 2× |
| daily iron supplementation (1 mg/kg/day) | Decreases - had a higher prevalence of | iron deficiency anemia (IDA) | Human | infants | Daily (1 mg/kg/day) or weekly (4 mg/kg/week) iron supplementation. | Effectiveness of weekly and daily iron administration for the prevention of iron deficiency anemia in infants.cited 2× |
| daily iron supplementation (1 mg/kg/day) | No effect - no significant differences in effectiveness were observed between | iron deficiency anemia (IDA) | Human | infants | Daily (1 mg/kg/day) or weekly (4 mg/kg/week) iron supplementation. | Effectiveness of weekly and daily iron administration for the prevention of iron deficiency anemia in infants.cited 2× |
| oral iron supplementation during the second half of pregnancy | Decreases - to reduce the risk of | maternal anemia and iron deficiency | Human | pregnancy | Not specified | Is Supplementation with Micronutrients Still Necessary during Pregnancy? A Review.cited 45× |
| high iron conditions | Increases - might promote | ineffective erythropoiesis and iron-loading anemia | Human | — | Not mentioned | Excess iron: considerations related to development and early growth.cited 54× |
| Simultaneous use of iron and vitamin A supplements | Decreases - seemed to be more effective | iron deficiency anemia | Human | — | Not specified | The influence of vitamin A supplementation on iron status.cited 31× |
| intravenous 500 mg iron sucrose treatment alone | No effect - is sufficient to treat postpartum anemia without the necessity of adding oral iron treatment | postpartum anemia | Human | women with postpartum anemia | 500 mg intravenous iron sucrose (single dose) and 60 mg oral iron bisglycinate daily for 45 days (for the combined group). | Addition of oral iron bisglycinate to intravenous iron sucrose for the treatment of postpartum anemia-randomized controlled trial.cited 4× |
| 500 mg intravenous iron sucrose | No effect - has not been evaluated | postpartum moderate to severe anemia | Human | women with postpartum anemia | 500 mg intravenous iron sucrose (single dose) and 60 mg oral iron bisglycinate daily for 45 days (for the combined group). | Addition of oral iron bisglycinate to intravenous iron sucrose for the treatment of postpartum anemia-randomized controlled trial.cited 4× |
| Daily supplementation with iron-folate | Decreases - was associated with reduction | anemia at term | Human | — | Daily supplementation (specific dosage not mentioned). | Effect of routine iron supplementation with or without folic acid on anemia during pregnancy.cited 58× |
| Daily supplementation with iron-folate | No effect - was non-significant | iron deficiency anemia | Human | — | Daily supplementation (specific dosage not mentioned). | Effect of routine iron supplementation with or without folic acid on anemia during pregnancy.cited 58× |
| Daily iron supplementation | Decreases - resulted in reduction | incidence of anemia at term | Human | — | Daily supplementation (specific dosage not mentioned). | Effect of routine iron supplementation with or without folic acid on anemia during pregnancy.cited 58× |
| Daily iron supplementation | Decreases - resulted in reduction | iron deficiency anemia at term | Human | — | Daily supplementation (specific dosage not mentioned). | Effect of routine iron supplementation with or without folic acid on anemia during pregnancy.cited 58× |
| intermittent iron-folate vs. daily iron-folate supplementation | No effect - There was no difference | rates of anemia at term | Human | — | Daily supplementation (specific dosage not mentioned). | Effect of routine iron supplementation with or without folic acid on anemia during pregnancy.cited 58× |
| efficient iron fortification methods | No effect - remains the most cost-effective and long-term approach | treatment of iron deficiency or related anemia | Human | — | Not specified | Treatments for Iron Deficiency (ID): Prospective Organic Iron Fortification.cited 9× |
| Oral supplementation of iron either from dietary or synthetic sources | No effect - has been the frontline therapy for treating | iron deficiency in anemia | Human | — | Not specified | Delivery systems for improving iron uptake in anemia.cited 7× |
| colloidal iron | Decreases - proportion became non-anemic | anemia status | Human | children with iron deficiency anemia | Elemental iron 3 mg/kg body weight per day. | Treatment of iron deficiency anemia in children: a comparative study of ferrous ascorbate and colloidal iron.cited 13× |
| iron via supplementation or the fortification of foods | Decreases - effective in preventing and treating | iron deficiency and iron deficiency anemia | Human | infants and young children | Not specified | Excess iron intake as a factor in growth, infections, and development of infants and young children.cited 86× |
| iron and erythropoiesis-stimulating agents (ESAs) | No effect - appropriateness for the treatment of | anemia | Human | patient living with CKD | Not mentioned | Considerations and controversies in managing chronic kidney disease: An update.cited 6× |
| intravenous iron sucrose | Increases - promising therapy | anemia treatment | Human | moderate to severely anemic pregnant women | Not specified | Is intravenous iron sucrose the treatment of choice for pregnant anemic women?cited 8× |
| oral iron | No effect - ineffectiveness | anemia treatment | Human | anemic pregnant women | Not specified | Is intravenous iron sucrose the treatment of choice for pregnant anemic women?cited 8× |
| proper health education of the pregnant women with nurse recommendations of balanced diet containing good sources of iron | Decreases - would help eradicate | iron deficiency anemia (IDA) with its serious sequel | Human | pregnant women | 100 mg lactoferrin oral sachets twice daily; total dose infusion of low-molecular weight iron dextran (specific dosage not detailed). | Lactoferrin plus health education versus total dose infusion (TDI) of low-molecular weight (LMW) iron dextran for treating iron deficiency anemia (IDA) in pregnancy: a randomized controlled trial.cited 5× |
| total dose infusion (TDI) of low-molecular weight (LMW) iron dextran | Decreases - showed a significant clinical improvement | anemia | Human | cases with iron deficiency anemia in the second and third trimester of pregnancy | 100 mg lactoferrin oral sachets twice daily; total dose infusion of low-molecular weight iron dextran (specific dosage not detailed). | Lactoferrin plus health education versus total dose infusion (TDI) of low-molecular weight (LMW) iron dextran for treating iron deficiency anemia (IDA) in pregnancy: a randomized controlled trial.cited 5× |
| iron supplements | Increases - exacerbate | iron deficiency anemia | Human | pregnant women | Not specified | Role of mineral nutrients other than iron in pregnancy: under recognized opportunities to improve maternal/fetal outcomes: a literature review. |
| two cycles of 20 daily doses of 30 mg elemental iron separated by a four-month period | No effect - no significant difference | anemia | Human | under five-year-old children who attended government daycare centers | Weekly Group: 30 mg elemental iron weekly (40 doses); Cyclical Group: two cycles of 20 daily doses of 30 mg elemental iron (40 doses total). | Cyclical iron supplementation to reduce anemia among Brazilian preschoolers: a randomized controlled trial.cited 5× |
| two cycles of 20 daily doses of 30 mg elemental iron separated by a four-month period | Decreases - showed a significant decrease | prevalence of anemia | Human | under five-year-old children who attended government daycare centers | Weekly Group: 30 mg elemental iron weekly (40 doses); Cyclical Group: two cycles of 20 daily doses of 30 mg elemental iron (40 doses total). | Cyclical iron supplementation to reduce anemia among Brazilian preschoolers: a randomized controlled trial.cited 5× |
| weekly doses of 30 mg elemental iron | No effect - no significant difference | anemia | Human | under five-year-old children who attended government daycare centers | Weekly Group: 30 mg elemental iron weekly (40 doses); Cyclical Group: two cycles of 20 daily doses of 30 mg elemental iron (40 doses total). | Cyclical iron supplementation to reduce anemia among Brazilian preschoolers: a randomized controlled trial.cited 5× |
| weekly doses of 30 mg elemental iron | Decreases - showed a significant decrease | prevalence of anemia | Human | under five-year-old children who attended government daycare centers | Weekly Group: 30 mg elemental iron weekly (40 doses); Cyclical Group: two cycles of 20 daily doses of 30 mg elemental iron (40 doses total). | Cyclical iron supplementation to reduce anemia among Brazilian preschoolers: a randomized controlled trial.cited 5× |
| screening and treatment of iron deficiency | No effect - is currently focused on detection of | anemia | HumanAnimal | children | Not specified | Approaches for Reducing the Risk of Early-Life Iron Deficiency-Induced Brain Dysfunction in Children.cited 52× |
| correction of iron deficiency | No effect - effects | iron deficiency independently of anemia | Human | patients with chronic kidney disease | Not specified | Unresolved aspects in the management of renal anemia, a Delphi consensus of the Anemia Group of the S.E.N. |
| iron supplementation with Fe | No effect - impact and management | iron deficiency with or without anemia | Human | patients with chronic kidney disease | Not specified | Unresolved aspects in the management of renal anemia, a Delphi consensus of the Anemia Group of the S.E.N. |
| iron-rich diet information and daily iron supplementation of ferrous sulfate | No effect - were informed about and received | anemia management | Human | women with iron deficiency | 80-160 mg of ferrous sulfate daily. | Anemia management in non-menopausal women in a primary care setting: a prospective evaluation of clinical practice.cited 3× |
| Routine addition of multi-micronutrients to iron-folate supplementation | No effect - appears unjustified currently | anemia | Human | — | Not specified | Preventing childhood anemia in India: iron supplementation and beyond.cited 24× |
| increased iron intake | Decreases - may yield maximum benefit but will only address up to half the burden | anemia burden | Human | — | Not specified | Preventing childhood anemia in India: iron supplementation and beyond.cited 24× |
| iron supplementation during treatment | No effect - no relevant role | resolution of anemia | Human | IBD patients | Not specified | Effects of anti-TNF-alpha therapy on hemoglobin levels and anemia in patients with inflammatory bowel disease.cited 9× |
| detecting anemia and iron deficiency and taking corrective measures well in advance of surgery | No effect - recommended | anemia and iron deficiency | Human | patients with moderate to high bleeding risk or known preoperative anemia | Not specified | Perioperative Patient Blood Management (excluding obstetrics): Guidelines from the French National Authority for Health.cited 6× |
| iron | Decreases - treat | anemia of chronic kidney disease (CKD) | Human | patients with chronic kidney disease | Not specified | Anemia in chronic kidney disease patients: treatment recommendations and emerging therapies.cited 19× |
| Addition of guava to a mungbean-based meal containing a moderate amount of iron | Decreases - reduced | anemia | Human | children | ~170 mg vitamin C daily (via guava) with 3.2 mg iron. | Vitamin C-Rich Guava Consumed with Mungbean Dal Reduces Anemia and Increases Hemoglobin but not Iron Stores: A Randomized Controlled Trial of Food-to-Food Fortification in Indian Children. |
| iron deficiency | Increases - adverse events documented | anemia | Human | pregnant postbariatric surgery patients | Not specified | Maternal nutritional status and related pregnancy outcomes following bariatric surgery: A systematic review.cited 50× |
| Iron deficiency | No effect - is the cause of | anemia | Human | patients with cardiac disease | Not specified | Perioperative Anemia Management as Part of PBM in Cardiac Surgery - A Narrative Updated Review.cited 36× |
| iron deficiency | No effect - emerges as the primary etiology for diagnosing | anemia | Human | — | 90 iron tablets during pregnancy (exact dosage per tablet not specified). | Normocytic Anemia in Pregnant Women: A Scoping Review.cited 1× |
| iron supplementation program | Decreases - is the main program for tackling | anemia | Human | pregnant women | 90 iron tablets during pregnancy (exact dosage per tablet not specified). | Normocytic Anemia in Pregnant Women: A Scoping Review.cited 1× |
| iron deficiency | No effect - is the most common cause | anemia and low red blood cell indices | Human | — | Not specified | Micronutrient Status in Sri Lanka: A Review.cited 11× |
| weekly iron supplementation with ferrous sulphate heptahydrate (FeSO4) | Decreases - reduced | anemia prevalence | Human | 5-year-olds | 50 mg elemental iron weekly | Weekly iron supplementation for the prevention of anemia in pre-school children: a randomized, double-blind, placebo-controlled trial.cited 7× |
| iron administration, both oral and IV iron | Decreases - improved | anemia | Human | ESA-treated cancer patients with CIA | Not specified | The addition of oral iron improves chemotherapy-induced anemia in patients receiving erythropoiesis-stimulating agents. |
| blood transfusion, iron supplementation, and erythropoietin | No effect - treated | severe anemia | Human | A 31-year-old Han Chinese female with menstrual disorders, increased menstrual flow, and severe anemia | Not specified | Pulmonary embolism after diagnostic curettage in patient with adenomyosis and hysteromyoma: A case report and brief review of literature. |
| pre-pregnancy weekly iron-folic acid (IFA) supplements | No effect - did not impact | anemia | Human | women | Weekly pre-pregnancy supplements: FA (2800 μg), IFA (60 mg Fe + 2800 μg FA), or MM (15 micronutrients, including 60 mg Fe + 2800 μg FA). Daily IFA (60 mg Fe + 400 μg FA) during pregnancy. | Impact of Preconception Micronutrient Supplementation on Anemia and Iron Status during Pregnancy and Postpartum: A Randomized Controlled Trial in Rural Vietnam.cited 33× |
| Long-term iron supplementation | Decreases - appears to result in a reduction in | anemia | Human | preterm and LBW infants | Not specified | Iron supplementation in preterm and low-birth-weight infants: a systematic review of intervention studies.cited 43× |
| enteral iron supplementation | Decreases - resulted in a reduction in | anemia | Human | preterm and low-birth-weight infants | Not specified | Iron supplementation in preterm and low-birth-weight infants: a systematic review of intervention studies.cited 43× |
| every other day iron supplementation | No effect - is as effective as daily intake | treating iron deficiency anemia | Human | anemic pregnant women | Not specified in the abstract. | Is every other day iron supplementation effective for the treatment of the iron deficiency anemia in pregnancy?cited 6× |
| insufficient iron supplementations | Increases - were high-risk factors for | postoperative anemia | Human | patients | Not specified | Prevalence of anemia and related nutrient deficiencies after sleeve gastrectomy: A systematic review and meta-analysis.cited 4× |
| routine iron supplementations | Decreases - may reduce | anemia after SG | Human | patients | Not specified | Prevalence of anemia and related nutrient deficiencies after sleeve gastrectomy: A systematic review and meta-analysis.cited 4× |
| iron supplementation daily for 2 months | No effect - had limited effect on | anemia at 6 mo | Human | children with anemia at baseline | Not specified for iron (only mentioned as "daily for 2 months"). | Supplementation of vitamin B12 or folic acid on hemoglobin concentration in children 6-36 months of age: A randomized placebo controlled trial.cited 8× |
| iron therapy | Decreases - treats | anemia | Human | women | Not specified | Forty to fifty-five-year-old women and iron deficiency: clinical considerations and quality of life.cited 9× |
| iron therapy | No effect - had no clinically relevant benefit | anemia associated with a hip fracture | Human | — | 28-day course of ferrous sulfate (specific dosage not mentioned). | Iron supplementation for anemia after hip fracture surgery: a randomized trial of 300 patients.cited 52× |
| Postoperative prophylactic iron and B12 supplementation, in addition to general multivitamin and mineral supplementation | No effect - is recommended based on the comparable deficiency risk | postoperative anemia and nutritional deficiencies | Human | bariatric patients | Not specified | Anemia, iron and vitamin B12 deficiencies after sleeve gastrectomy compared to Roux-en-Y gastric bypass: a meta-analysis.cited 87× |
| oral or intravenous iron supplementation | No effect - many patients remain anemic and do not respond | anemia | Human | patients | Not specified | Cancer Related Anemia: An Integrated Multitarget Approach and Lifestyle Interventions.cited 22× |
| weekly iron-folic acid (IFA) | Decreases - indicate potential protective effects | anemia | Human | adolescents (secondary school students aged 10 to 18 y in Burkina Faso) | Weekly IFA or daily MMS (specific amounts not detailed in the abstract). | School-based supplementation with iron-folic acid or multiple micronutrient tablets to address anemia among adolescents in Burkina Faso: a cluster-randomized trial.cited 2× |
| weekly iron-folic acid (IFA) | No effect - No significant associations were observed | anemia outcomes | Human | adolescents (secondary school students aged 10 to 18 y in Burkina Faso) | Weekly IFA or daily MMS (specific amounts not detailed in the abstract). | School-based supplementation with iron-folic acid or multiple micronutrient tablets to address anemia among adolescents in Burkina Faso: a cluster-randomized trial.cited 2× |
| i.v. iron combined with rHuEPO | No effect - show similar efficacy | treatment of anemia | Human | advanced cancer patients undergoing chemotherapy | Ferric gluconate (125 mg i.v. weekly) or lactoferrin (200 mg/day) | Efficacy and safety of oral lactoferrin supplementation in combination with rHuEPO-beta for the treatment of anemia in advanced cancer patients undergoing chemotherapy: open-label, randomized controlled study.cited 48× |
| oral iron therapy | No effect - is the first-line treatment for | iron deficiency anemia | Human | — | 3 to 6 mg/kg of elemental iron per day (for treatment, not dietary counseling specifically). | Iron Deficiency Anemia: An Updated Review.cited 24× |
| oral iron therapy | No effect - was only documented | treatment for anemia | Human | patients with collagenous gastritis | Various treatments included oral iron (12 patients), proton pump inhibitors (12), histamine-2 blockers (3), sucralfate (5), prednisolone (6), and oral budesonide (3). | Clinical outcome of pediatric collagenous gastritis: case series and review of literature.cited 31× |
| new oral iron therapy products | No effect - effective in treating | anemia of inflammation | Human | — | Not specified | Update on iron supplementation in patients with cancer-related anemia. |
| IV iron | No effect - affirm the efficacy and safety | cancer-related anemia (CRA) | Human | — | Not specified | Update on iron supplementation in patients with cancer-related anemia. |
| IV iron | No effect - remains underutilized | cancer-related anemia (CRA) | Human | — | Not specified | Update on iron supplementation in patients with cancer-related anemia. |
| Oral iron | Decreases - is effective | anemia | Human | patients able to tolerate | Oral iron with every other day dosing; IV iron dosage not specified. | Iron deficiency anemia in pregnancy.cited 8× |
| universal IV iron supplementation | Decreases - provide consideration for | anemia | Human | beyond 34 weeks of pregnancy | Oral iron with every other day dosing; IV iron dosage not specified. | Iron deficiency anemia in pregnancy.cited 8× |
| IV iron | Decreases - are more likely to benefit from | anemia | Human | Pregnant people with IDA in the third trimester | Oral iron with every other day dosing; IV iron dosage not specified. | Iron deficiency anemia in pregnancy.cited 8× |
| co-administration of DFAIII with water-insoluble iron | No effect - investigated the efficacy of | iron deficiency anemia | Human | Vietnamese women | 15 mg Fe as ferric pyrophosphate or ferrous sulfate, with or without 1.25 g DFAIII, daily. | Difructose anhydride III enhances bioavailability of water-insoluble iron in anemic Vietnamese women.cited 6× |
| formula milk fortified with 1.2 mg/100 mL of iron | Decreases - lower percentage of | iron deficiency anemia | Human | Spanish children | 1.2 mg/100 mL or 0.4 mg/100 mL of iron in formula milk. | Does the fortified milk with high iron dose improve the neurodevelopment of healthy infants? Randomized controlled trial.cited 7× |
| iron supplementation and multivitamins (vitamins A, C, and D) | Decreases - reduced the risk of | anemia persisting for up to 6 months follow-up | Human | HIV-infected Malawian children aged 6-59 months with moderate anemia | 3 mg/kg/day of elemental iron with multivitamins (vitamins A, C, and D). | Iron supplementation in HIV-infected Malawian children with anemia: a double-blind, randomized, controlled trial.cited 47× |
| iron fortification and supplementation | Decreases - can be treated | anemia | Human | patients with low body iron levels | Not specified | Iron: effect of overload and deficiency.cited 35× |
| multiple micronutrient supplementation (MMS) with 5 mg of iron (ferrous sulfate) | Decreases - reduced | anemia | Human | fourth-grade students in poor areas of rural China | 5 mg of iron (ferrous sulfate) daily as part of MMS. | Multiple micronutrient supplementation reduces anemia and anxiety in rural China's elementary school children.cited 27× |
| multiple micronutrient supplementation (MMS) with 5 mg of iron (ferrous sulfate) | Decreases - reduced | anemia rates | Human | fourth-grade students in poor areas of rural China | 5 mg of iron (ferrous sulfate) daily as part of MMS. | Multiple micronutrient supplementation reduces anemia and anxiety in rural China's elementary school children.cited 27× |
| direct observation of oral iron supplementation | Decreases - reduction in the prevalence | prevalence of anemia | Human | — | Not specified | Directly observed iron supplementation for control of iron deficiency anemia.cited 9× |
| Weekly supplementation with 120mg iron plus various amounts of folic acid | Decreases - similarly prevents significant anemia | significant anemia | Human | — | Daily (60-120mg iron + 0.4mg folic acid) or weekly (120mg iron + varying folic acid). | Antenatal iron supplements consumed daily produce oxidative stress in contrast to weekly supplementation in Mexican non-anemic women.cited 32× |
| Universal prenatal daily supplementation with iron (60-120mg iron) plus folic acid (0.4mg) | Decreases - prevents anemia | anemia | Human | where iron deficiency is prevalent | Daily (60-120mg iron + 0.4mg folic acid) or weekly (120mg iron + varying folic acid). | Antenatal iron supplements consumed daily produce oxidative stress in contrast to weekly supplementation in Mexican non-anemic women.cited 32× |
| standard treatment with iron supplementation | No effect - do not respond to | anemia | Human | pediatric patients | Not available | Anemia in Childhood.cited 9× |
| iron and folic acid supplementation | No effect - persists | anemia | Human | breastfeeding women | Not specified | Anemia in Breastfeeding Women and Its Impact on Offspring's Health in Indonesia: A Narrative Review.cited 1× |
| Double-fortified salt (DFS) containing iron and iodine | Decreases - reduced | risk of anemia | Human | school-age children | Not specified | Impact of Double-Fortified Salt with Iron and Iodine on Hemoglobin, Anemia, and Iron Deficiency Anemia: A Systematic Review and Meta-Analysis.cited 27× |
| Double-fortified salt (DFS) containing iron and iodine | Decreases - efficacious in reducing | risk of anemia | Human | LMIC populations | Not specified | Impact of Double-Fortified Salt with Iron and Iodine on Hemoglobin, Anemia, and Iron Deficiency Anemia: A Systematic Review and Meta-Analysis.cited 27× |
| Double-fortified salt (DFS) containing iron and iodine | Decreases - reduced | risk of anemia | Human | efficacy studies | Not specified | Impact of Double-Fortified Salt with Iron and Iodine on Hemoglobin, Anemia, and Iron Deficiency Anemia: A Systematic Review and Meta-Analysis.cited 27× |
| Double-fortified salt (DFS) containing iron and iodine | Decreases - reduced | risk of iron deficiency anemia (IDA) | Human | efficacy studies | Not specified | Impact of Double-Fortified Salt with Iron and Iodine on Hemoglobin, Anemia, and Iron Deficiency Anemia: A Systematic Review and Meta-Analysis.cited 27× |
| Double-fortified salt (DFS) containing iron and iodine | Decreases - reduced | risk of iron deficiency anemia (IDA) | Human | school-age children | Not specified | Impact of Double-Fortified Salt with Iron and Iodine on Hemoglobin, Anemia, and Iron Deficiency Anemia: A Systematic Review and Meta-Analysis.cited 27× |
| Double-fortified salt (DFS) containing iron and iodine | Decreases - efficacious in reducing | risk of iron deficiency anemia (IDA) | Human | LMIC populations | Not specified | Impact of Double-Fortified Salt with Iron and Iodine on Hemoglobin, Anemia, and Iron Deficiency Anemia: A Systematic Review and Meta-Analysis.cited 27× |
| iron-based therapies | Decreases - reduced | maternal anemia at term | Human | pregnant women | Not specified | Oral iron-based interventions for prevention of critical outcomes in pregnancy and postnatal care: An overview and update of systematic reviews.cited 20× |
| iron-based therapies | No effect - insufficient evidence to determine whether can reduce | postpartum anemia | Human | postpartum women | Not specified | Oral iron-based interventions for prevention of critical outcomes in pregnancy and postnatal care: An overview and update of systematic reviews.cited 20× |
| parenteral iron supplementation | Decreases - only partially corrected | anemia | Human | CKD patients with anemia | Not specified | Hepcidin is a potential regulator of iron status in chronic kidney disease.cited 27× |
| parenteral iron supplementation | No effect - is the second main form of anemia treatment | anemia treatment | Human | — | Not specified | Iron dosing in kidney disease: inconsistency of evidence and clinical practice.cited 23× |
| serial recombinant erythropoietin combined with iron supplementation | Increases - was more effective at treating | refractory iron deficiency anemia | Human | pregnant patients | Not specified (varied by study, with some using serial doses and others a single dose). | Recombinant erythropoietin for the treatment of iron deficiency anemia in pregnancy: A systematic review.cited 2× |
| supplementation of iron and erythropoietin alone | No effect - often does not lead to correction | anemia | Human | patients with persistent nephrotic syndrome | Not specified | Anemia in nephrotic syndrome: approach to evaluation and treatment.cited 16× |
| enteral iron supplementation | Decreases - an improvement in | anemia | Human | preterm or LBW infants fed human milk | Not specified | Enteral Iron Supplementation in Preterm or Low Birth Weight Infants: A Systematic Review and Meta-analysis.cited 15× |
| high-zinc, low-iron micronutrient powder (10 mg/d zinc, 6 mg/d iron, and 13 other micronutrients) | No effect - had no overall impact | anemia | Human | young Laotian children aged 6-23 months | 6 mg/d iron (as part of a micronutrient powder containing 10 mg/d zinc and 13 other micronutrients). | Effects of Daily Zinc, Daily Multiple Micronutrient Powder, or Therapeutic Zinc Supplementation for Diarrhea Prevention on Physical Growth, Anemia, and Micronutrient Status in Rural Laotian Children: A Randomized Controlled Trial.cited 34× |
| high-zinc, low-iron micronutrient powder (10 mg/d zinc, 6 mg/d iron, and 13 other micronutrients) | Decreases - tended to reduce | anemia | Human | children who were anemic at baseline | 6 mg/d iron (as part of a micronutrient powder containing 10 mg/d zinc and 13 other micronutrients). | Effects of Daily Zinc, Daily Multiple Micronutrient Powder, or Therapeutic Zinc Supplementation for Diarrhea Prevention on Physical Growth, Anemia, and Micronutrient Status in Rural Laotian Children: A Randomized Controlled Trial.cited 34× |
| supplementary iron | Decreases - reduction | maternal anemia risk | Human | pregnant women | Not specified | Oral Iron Supplementation in Pregnancy: Current Recommendations and Evidence-Based Medicine.cited 3× |
| iron-folate supplementation | Decreases - can be reduced | anemia | Human | women in poor countries | Not specified | Opportunities for improving maternal nutrition and birth outcomes: synthesis of country experiences.cited 32× |
| directly observed home-based daily iron therapy | Decreases - significantly lower relative risk | anemia | Human | anemic women and adolescent girls | Not specified in the abstract. | A community-based cluster randomized controlled trial of "directly observed home-based daily iron therapy" in lowering prevalence of anemia in rural women and adolescent girls.cited 8× |
| iron interventions | Decreases - proven effectiveness | anemia treatment and prevention | Human | — | Not specified | Effect of Anemia on Work Productivity in Both Labor- and Nonlabor-Intensive Occupations: A Systematic Narrative Synthesis.cited 10× |
| saccharide-iron (III) complexes (SICs) | Increases - exhibited good abilities in | treating anemia | Human | — | Not specified. | Advances on novel iron saccharide-iron (III) complexes as nutritional supplements.cited 7× |
| interventions including increasing iron supply and simultaneously increasing its absorption by vitamin C supply | Increases - were all results confirmed effective | treatment of iron-deficiency anemia | Human | women of childbearing age | Not specified | Effectiveness of Dietary Interventions to Treat Iron-Deficiency Anemia in Women: A Systematic Review of Randomized Controlled Trials.cited 9× |
| daily oral iron supplementation | No effect - had no significant effect | iron deficiency anemia | Human | exclusively breastfed infants | Not specified | Effect of Daily Iron Supplementation in Healthy Exclusively Breastfed Infants: A Systematic Review with Meta-Analysis.cited 13× |
| daily oral iron supplementation | Decreases - probably reduces | iron deficiency anemia at term | Human | iron replete non-anemic pregnant women | Not specified | Iron supplements in pregnant women with normal iron status: A systematic review and meta-analysis.cited 12× |
| Erythropoiesis-stimulating agents (ESAs) together with iron supplementation | No effect - had been the standard treatment | anemia | Human | chronic kidney disease (CKD) | Not mentioned | A spotlight on using HIF-PH inhibitors in renal anemia.cited 5× |
| iron /foliate supplementation | Decreases - shall focus on prevention | anemia related maternal mortality and morbidity | Human | immediate postpartum women in Ethiopia | Not specified | The magnitude and associated factors of immediate postpartum anemia among women who gave birth in Ethiopia: systematic review and meta-analysis, 2023.cited 1× |
| weekly antenatal oral iron and folate supplementation | No effect - is an effective alternative to a daily regimen | preventing anemia and iron deficiency | Human | non-anemic pregnant women | Weekly group: 120 mg elemental iron, 3 mg folic acid, and 100 mg vitamin C weekly; Daily group: 60 mg elemental iron, 1 mg folic acid, and 100 mg vitamin C daily. | Randomized control trial comparing effectiveness of weekly versus daily antenatal oral iron supplementation in preventing anemia during pregnancy.cited 10× |
| weekly antenatal oral iron and folate supplementation | No effect - no significant differences | risk of developing anemia | Human | non-anemic pregnant women | Weekly group: 120 mg elemental iron, 3 mg folic acid, and 100 mg vitamin C weekly; Daily group: 60 mg elemental iron, 1 mg folic acid, and 100 mg vitamin C daily. | Randomized control trial comparing effectiveness of weekly versus daily antenatal oral iron supplementation in preventing anemia during pregnancy.cited 10× |
| dietary interventions based on providing increased amount of iron | Decreases - were effective | prevention and treatment of iron-deficiency anemia | Human | pregnant women | Not specified | Effectiveness of Dietary Interventions in Prevention and Treatment of Iron-Deficiency Anemia in Pregnant Women: A Systematic Review of Randomized Controlled Trials.cited 9× |
| 80 mg/d iron supplementation | Decreases - protected against | anemia | Human | women with ID on week 12 | 20 mg/d, 40 mg/d, or 80 mg/d, depending on hemoglobin stratum. | The Effectiveness of Different Doses of Iron Supplementation and the Prenatal Determinants of Maternal Iron Status in Pregnant Spanish Women: ECLIPSES Study.cited 20× |
| 80 mg/d iron supplementation | Decreases - protected against | iron deficiency anemia (IDA) | Human | women with ID on week 12 | 20 mg/d, 40 mg/d, or 80 mg/d, depending on hemoglobin stratum. | The Effectiveness of Different Doses of Iron Supplementation and the Prenatal Determinants of Maternal Iron Status in Pregnant Spanish Women: ECLIPSES Study.cited 20× |
| 12.5 mg elemental iron once daily | Decreases - reducing | anemia prevalence | Human | infants aged 12-24 months | 25 mg elemental iron once weekly (Group A); 12.5 mg elemental iron once daily (Group B). | Daily and Weekly Iron Supplementations are Effective in Increasing Hemoglobin and Reducing Anemia in Infants.cited 5× |
| 25 mg elemental iron once weekly | Decreases - reducing | anemia prevalence | Human | infants aged 12-24 months | 25 mg elemental iron once weekly (Group A); 12.5 mg elemental iron once daily (Group B). | Daily and Weekly Iron Supplementations are Effective in Increasing Hemoglobin and Reducing Anemia in Infants.cited 5× |
| iron and folic acid (IFA) supplementation program | No effect - has remained high | prevalence of anemia | Human | Indian adolescent girls | Experimental group: iron (60 mg), folic acid (500 mcg), cyanocobalamin (1000 mcg) daily; control group: IFA (iron 60 mg, folic acid 500 mcg) and placebo daily. | Impact of daily-supervised administration of a package of iron and folic acid and vitamin Bcited 6× |
| iron supplement | Decreases - significantly decreased the proportion of | anemia | Human | women in the intervention group | Not specified | A Novel School-based Intermittent Delivery System of Iron Supplements for Highly Marginalized Tarahumara Indigenous Women of Reproductive Age of Northern Mexico.cited 2× |
| Iron supplement | No effect - have become the treatment of choice | Chronic Kidney Disease (CKD) anemia | Human | patients undergoing End Stage Renal Disease (ESRD) | Not specified | A new machine learning approach for predicting the response to anemia treatment in a large cohort of End Stage Renal Disease patients undergoing dialysis.cited 39× |
| IV iron | Increases - significantly improved | anemia | Human | cancer patients with anemia | Not specified | Intravenous Iron as an Alternative to Blood Transfusion in Cancer Patients: A Single Center Experience. |
| IV iron | Increases - appears to be more effective and better tolerated than oral iron | treatment of IBD-associated anemia | Human | IBD patients | Not specified in the abstract. | Intravenous Versus Oral Iron for the Treatment of Anemia in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.cited 73× |
| lactoferrin and iron hydroxide polymaltose | Decreases - Positive results included | iron deficiency anemia | Human | children with cerebral palsy | Not specified | Dietary and nutritional interventions in children with cerebral palsy: A systematic literature review.cited 3× |
| iron supplement treatment | Decreases - was beneficial to prevent | anemia | Human | women who delivered vaginally ≥ 36 gestational weeks | Not specified | Prediction of anemia at delivery.cited 6× |
| iron supplement treatment | Increases - was an independent risk factor for | anemia at delivery | Human | women who delivered vaginally ≥ 36 gestational weeks | Not specified | Prediction of anemia at delivery.cited 6× |
| intravenous iron to supplement erythropoiesis stimulating agents (ESAs) | No effect - has become a common practice | management of anemia | Human | patients with end-stage renal disease | Not specified | Iron overdose: a contributor to adverse outcomes in randomized trials of anemia correction in CKD.cited 30× |